SYS-CON MEDIA Authors: Yeshim Deniz, Doug Masi, Mat Mathews, PR.com Newswire, David Smith

News Feed Item

Diabetic Macular Edema Market (BRVO & CRVO) Epidemiology Forecast to 2023 New Report Available at MarketOptimizer.org

MarketOptimizer.org adds new report "Epicast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023" to its store.

DALLAS, Sept. 3, 2014 /PRNewswire-iReach/ -- Macular edema (ME) occurs due to the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. In ME, fluid and protein deposits collect on or under the macula of the eye, due to a breakdown in the blood-retinal barrier. The occurrence of ME is highly frequent in diabetics and usually manifests itself as diabetic macular edema (DME). DME is often a complication of diabetic retinopathy, and is the most common cause of vision loss in individuals with diabetes, especially if left untreated. The risk for ME is high in patients with retinal vein occlusion (RVO), which consists of two types: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).

Photo - http://photos.prnewswire.com/prnh/20140903/142483

Epidemiologists forecast that the diagnosed prevalent cases of DME in the diagnosed diabetic retinopathy population in the 7MM will increase by 34.2% during the forecast period, from 922,492 cases in 2013 to 1,238,301 cases in 2023. The total prevalent cases of ME following BRVO in the 7MM will increase by 13.7% during the forecast period, from 294,862 cases in 2013 to 335,346 cases in 2023. The total prevalent cases of ME following CRVO in the 7MM will increase by 19.6% during the forecast period, from 114,571 cases in 2013 to 136,973 cases in 2023.

Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=10264 .

Epidemiological analysis is supported by the use of country-specific prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the diagnosed prevalent cases of DME in the diagnosed diabetic retinopathy population and the total prevalent cases of ME following BRVO and CRVO, to allow for a meaningful comparison of the disease populations across markets.

Scope

  • The Diabetic Macular Edema (DME) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and the global and historical trends for DME in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DME in the diagnosed diabetic retinopathy population and the total prevalent cases of ME following branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) segmented by sex and age (20–39 years, 40–59 years, 60–79 years, and =80 years) in these markets.
  • The DME epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
  • The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Complete Report Details @ http://www.marketoptimizer.org/epicast-report-diabetic-macular-edema-epidemiology-forecast-to-2023.html .

Reasons to Buy

  • Develop business strategies by understanding the trends shaping and driving the global DME market.
  • Quantify patient populations in the global DME market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for DME therapeutics in each of the markets covered.
  • Identify the number of ME cases following BRVO and CRVO.

Major Points in Table of Content

1 Table of Contents

2 Executive Summary

3 Introduction

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global Trends

4.3.1 US

4.3.2 5EU

4.3.3 Japan

4.4 Forecast Methodology

4.4.1 Sources Used

4.4.2 Sources Not Used

4.4.3 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetes

4.4.4 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetic Retinopathy

4.4.5 Forecast Assumptions and Methods – Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population

4.4.6 Forecast Assumptions and Methods – Total Prevalent Cases of ME following BRVO and CRVO

4.5 Epidemiological Forecast for Macular Edema (2013–2023)

4.5.1 Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population

4.5.2 Age-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population

4.5.3 Sex-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population

4.5.4 Total Prevalent Cases of ME following BRVO

4.5.5 Age-Specific Total Prevalent Cases of ME following BRVO

4.5.6 Sex-Specific Total Prevalent Cases of ME following BRVO

4.5.7 Total Prevalent Cases of ME following CRVO

4.5.8 Age-Specific Total Prevalent Cases of ME following CRVO

4.5.9 Sex-Specific Total Prevalent Cases of ME following CRVO

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 Limitations of the Analysis

4.6.3 Strengths of the Analysis

Inquire Before Buying @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=10264 .

(This is a premium report priced at US$3995 for a single user License)

List of Tables

Table 1: Risk Factors for DME

Table 2: Comorbidities for DME

Table 3: 7MM, Sources of Diagnosed Prevalence of DME in the Diagnosed Diabetic Retinopathy Population

Table 4: 7MM, Sources of Total Prevalence of ME following BRVO and CRVO

Table 5: 7MM, Sources Not Used in Epidemiological Analysis of DME

Table 6: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, Ages =20 Years, Both Sexes, N, 2013–2023

Table 7: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Age, Both Sexes, N, (Row %), 2013

Table 8: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Sex, Ages =20 Years, N (Row %), 2013

Table 9: 7MM, Total Prevalent Cases of ME following BRVO, Ages =20 Years, Both Sexes, N, 2013–2023

Table 10: 7MM, Total Prevalent Cases of ME following BRVO, by Age, Both Sexes, N, (Row %), 2013

Table 11: 7MM, Total Prevalent Cases of ME following BRVO, by Sex, Ages =20 Years, N (Row %), 2013

Explore more reports on Pharmaceuticals industry at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals .

About Us:

MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Media Contact: Ritesh Tiwari, MarketOptimizer, +18883915441, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE MarketOptimizer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.